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Chapter 4.1: Contrast-induced AKI: definition,
epidemiology, and prognosis
BACKGROUND
Contrast-related acute kidney problems are frequent and
occur in both ambulatory and hospitalized patients. Since
there is accumulating evidence that many risk factors,
preventive measures, and the immediate and long-term
prognosis of these problems are common to the other causes
of AKI, the Work Group believes that there is a need for a
unifying definition for all forms of AKI and therefore
proposes that the term contrast-induced acute kidney injury
(CI-AKI) be used for patients developing AKI secondary to
intravascular radiocontrast media exposure.
The literature on CI-AKI is predominantly related to AKI
following iodinated contrast-media administration. As will
be discussed in Appendix E, non–iodine contrast media—
notably Gd-containing contrast media—may also occasion-
ally induce AKI.
4.1: Define and stage AKI after administration of intra-
vascular contrast media as per Recommendations
2.1.1–2.1.2. (Not Graded)
4.1.1: In individuals who develop changes in
kidney function after administration of intra-
vascular contrast media, evaluate for CI-AKI
as well as for other possible causes of AKI.
(Not Graded)
RATIONALE
Pending the validation of future biomarkers which would
allow a more straightforward comparison and integration of
CI-AKI in the overall framework of AKI, we suggest that the
same criteria, using the changes in SCr concentrations and
urine output be used as for the other forms of AKI. The Work
Group is not aware of any pathophysiological or epidemio-
logical reason why the definition and staging of CI-AKI
should be different from the RIFLE/AKIN criteria. It should,
however, be stressed that for the development of this
guideline, the term contrast-induced nephropathy is widely
used in the literature and usually defined as a rise in SCr
of X0.5mg/dl (X44 mmol/l) or a 25% increase from base-
line value, assessed at 48 hours after a radiological proce-
dure. This definition also consistently predicted major
adverse cardiovascular events after percutaneous coronary
intervention.385 The Society of Urogenital Radiology used the
same definition, but the creatinine changes were said to occur
within 3 days after intravascular administration of contrast
media without an alternative etiology.386 It should be
recognized that, in a minority of cases, the peak increase of
SCr may occur up until 5 days after contrast exposure.
However, a recent prospective study387 showed that the
percentage change of SCr 12 h after contrast vs. the basal
value was the best predictor of CI-AKI (Po0.001). A 5%
increase of its value yielded 75% sensitivity and 72%
specificity, with an area under the curve (AUC) of 0.80 and
an OR of 7.37 (95% CI 3.34–16.23) for early detection.
Furthermore, this 12-hour basal value strongly correlated
with the development of renal impairment at 30 days
(P¼ 0.002; sensitivity 87%, specificity 70%; AUC 0.85; OR
13.29; 95% CI 2.91–60.64).
It has been shown that substantial variation in SCr may
occur from day to day in hospitalized patients who do not
receive contrast-media injections.388 Depending on the
threshold criterion for CI-AKI chosen, this variation can
lead to rates of 6–35% of inpatients, not exposed to contrast
media, who would be labeled as having CI-AKI had they
received contrast media. The exact cause of this ‘‘hospital-
induced nephropathy’’389 is not known, but other studies
have shown that AKI (various etiologies) is common in
hospitalized patients.
The magnitude of the impact of the ‘‘background
fluctuation of kidney function’’ in patients receiving iodinated
contrast has not been prospectively studied, but a recent retro-
spective study compared the incidence of AKI among patients
undergoing enhanced computed tomography (CT) with i.v.
low-osmolar (iohexol) or iso-osmolar (iodixanol) contrast
media to the AKI incidence among patients undergoing CT
without contrast-media administration.390 The incidence of
AKI (defined as an increase of SCr of 0.5mg/dl [44mmol/l] or
aX25% decrease in eGFR within 3 days after CT) was similar
in all three groups (two receiving contrast agents and one not)
up to a baseline SCr level of 1.8mg/dl (159mmol/l). A high
incidence of ‘‘AKI’’ among control subjects undergoing
noncontrast CT was thus identified. Given the results of this
retrospective study, it is clear that AKI after i.v. administration
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of iodine contrast media cannot be automatically attributed
to the contrast agent, but may, in fact, reflect AKI from other
causes, such as worsening underlying disease or drug toxicity.
Therefore, the Work Group strongly recommends that
individuals showing increases of SCr compatible with the
definition of AKI after administration of intravascular contrast
media be also evaluated for other possible causes of AKI.
In a study using cystatin C as an early marker for AKI,
a cut-off cystatin C increase concentration of X10% at 24
hours after contrast-media exposure was detected in 87
patients (21.2%), and was the best cut-off value for the early
identification of patients at risk for CI-AKI with a negative
predictive value of 100% and a positive predictive value of
39%. As in other cases of AKI, it appears that, in patients
with CKD, cystatin C may be a useful marker for the early
diagnosis of CI-AKI.
Epidemiology of CI-AKI
Keeping the above-mentioned problems of definition in
mind, it is not surprising that the reported incidence of
CI-AKI varies widely across the literature, depending on the
definitions used, the patient population, and the baseline risk
factors.
The. impact of different definitions on the incidence of
CI-AKI can be illustrated by the recent results of the Oxilan
Registry.391 In this registry, CI-AKI was defined as either a
SCr increase 40.5mg/dl (444 mmol/l), or a SCr increase
425%, or a decrease 425% of eGFR, or the composite of
all three definitions. The baseline SCr was 1.12 ± 0.3mg/dl
(99 ± 26.5 mmol/l) and 24% had an eGFR o60ml/min.
CI-AKI rates were 3.3% (SCr increase 40.5mg/dl
[444 mmol/l]), 10.2% (SCr increase 425%), 7.6% (eGFR
decrease 425%), and 10.5% (composite), respectively.
It is accepted that, in patients with normal renal function—
even in the presence of diabetes—the risk for CI-AKI is low
(1–2%).392 However, the incidence may be as high as 25% in
patients with pre-existing renal impairment or in presence of
certain risk factors, such as the combination of CKD and
diabetes, CHF, advanced age, and concurrent administration
of nephrotoxic drugs.393 CI-AKI was described as the third
most common cause of new AKI in hospitalized patients
(after decreased renal perfusion and nephrotoxic medications)
and was responsible for 11% of cases.394
The epidemiology of de novo CI-AKI in critically ill
patients is not known. In a group of 75 ICU patients with a
normal baseline SCr who were exposed to CT scans with an
i.v. low-osmolar contrast medium, an increase in SCr425%
was recorded in 18% of the patients. There was no change of
the SCr in a control group of patients undergoing CT scans
but not receiving contrast media.395 This rather small study
shows that in critically ill patients, even with an apparently
‘‘normal’’ renal function, i.v. administration of iodinated
contrast media is associated with a significant incidence of
CI-AKI.
It could be expected that radiological procedures
performed in an emergency would be associated with an
increased risk of CI-AKI but, as recently summarized,396
the published evidence to support this premise is rather
scarce.397
Prognosis of CI-AKI
Many studies have now shown that patients who develop
CI-AKI have a greater risk for death or prolonged hospitali-
zation, as well as for other adverse outcomes, including early
or late cardiovascular events. The latter are more common
after, for example, percutaneous coronary interventions (for
review, see McCullough398). In a retrospective analysis
including 27 608 patients who underwent coronary angio-
graphy at the University of Pittsburgh Medical Center during
a 12-year period, discrete proportional odds models were
used to examine the association between increases in SCr and
30-day in-hospital mortality and LOS, respectively. It appea-
red that small absolute (0.25–0.5mg/dl [22–44 mmol/l]) and
relative (25–50%) increases in SCr were associated with
risk-adjusted OR for in-hospital mortality of 1.83 and 1.39,
respectively; larger increases in SCr generally were associated
with greater risks for these clinical outcomes.399 Moreover,
when patients with CI-AKI require dialysis, the mortality is
higher compared to those not requiring dialysis. For example,
in the study by McCullough et al.,400 the hospital mortality
was 7.1% in CI-AKI and 35.7% in patients who required
dialysis. By 2 years, the mortality rate in patients who
required dialysis was 81.2%.
The more recent Cardiac Angiography in Renally
Impaired Patients study401—a large, multicenter, prospective,
double-blind RCT of patients who had moderate to severe
CKD and were undergoing cardiac angiography—also
showed that the adjusted incidence rate ratio for adverse
events was twice as high in those with CI-AKI. However,
these data demonstrating a temporal association between CI-
AKI and short or long-term prognosis do not establish a
causal relationship, since most of the patients in these
observational studies have underlying risk factors that, in
addition to increasing the patient’s risk of CI-AKI, can
directly increase their overall risk for the complications
studied. Finally, many of the retrospective studies may also
have introduced selection bias for patients who presumably
had a clinical reason for having their SCr concentration
followed.
Data on the association between risk of ESRD and CI-AKI
are scarce. In contemporary studies, CI-AKI requiring
dialysis developed in almost 4% of patients with underlying
renal impairment and 3% of patients undergoing primary
percutaneous coronary interventions for acute coronary
syndrome. However, only a small proportion of patients
continued on chronic dialysis.402,403 Although CI-AKI
requiring dialysis is relatively rare, the impact on patient
prognosis is considerable, with high hospital and 1-year
mortality rates (for a review, see McCullough398). Only one
study404 reported the incidence of new CKD Stage 4–5
(eGFRo30ml/min) following percutaneous coronary inter-
ventions and found that this occurred in 0.3% of patients
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with an eGFR 430ml/min at baseline and newly diagnosed
kidney disease within 6 months after the procedure, and in
0.9% of patients with an eGFR460ml/min at baseline. These
percentages are higher than the estimated annual incidence of
CKD at 0.17% that was found in a British general population
cohort over a 5.5-year period of follow-up.405 Thus, careful
long-term follow-up of SCr following contrast exposure is
warranted.
RESEARCH RECOMMENDATION
K Large prospective RCTs examining the epidemiology of
CI-AKI are needed, especially on long-term outcomes,
with attention to controlling for confounders.
SUPPLEMENTARY MATERIAL
Appendix E: Risks with Gadolinium-Based Contrast Agents.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/AKI.php
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Chapter 4.2: Assessment of the population at risk
for CI-AKI
At present, millions of doses of intravascular contrast
media are being administered worldwide.406,407 Most of
these radiological examinations are performed in ambu-
latory populations who do not need special preventive
measures. However, contrast media are also increasingly used
in an elderly population, many of whom have CKD and
diabetes—the principal risk factors for CI-AKI. It is, thus,
of utmost importance to screen the population at risk for
CI-AKI.
4.2.1: Assess the risk for CI-AKI and, in particular,
screen for pre-existing impairment of kidney
function in all patients who are considered for a
procedure that requires intravascular (i.v. or i.a.)
administration of iodinated contrast medium.
(Not Graded)
RATIONALE
Screening for pre-existing impairment of kidney function
Pre-existing renal functional impairment is the most
important risk factor above all other risk factors for
developing CI-AKI408 and screening for both acute and
chronic kidney disease is highly recommended. There is no
sharp GFR threshold below which the risk for CI-AKI is
clearly increasing. Both the KDOQI guideline and KDIGO
recommend that, in stable patients, an eGFR should be
used.409
A CI-AKI Consensus Working Panel410 agreed that the risk
of CI-AKI becomes clinically important when the baseline
SCr concentration is X1.3mg/dl (X115 mmol/l) in men and
X1.0mg/dl (X88.4 mmol/l) in women, equivalent to an
eGFR o60ml/min per 1.73 m2. However, Bruce et al.390
showed that the incidence of ‘‘true’’ AKI became significant
only between controls and contrast-media administered
patients from a baseline SCr concentration of 41.8mg/dl
(4159 mmol/l) onward. The CI-AKI Consensus Working
Panel410 recommended that precautions to reduce the risk
should be implemented in patients with a baseline
eGFRo60ml/min per 1.73 m2. In light of more recent
information, this threshold could probably be lowered to
45ml/min per 1.73 m2.
In many institutions, point-of-care SCr testing is present,
and the results can be available quite fast. In places without
point-of-care laboratories, the appropriate blood tests should
be requested, but an emergent imaging/intervention, where
the benefit of very early imaging outweighs the risk of
waiting, should not be delayed.
For its relative simplicity, only SCr is used at many
hospitals to determine whether a patient is a candidate
for intravascular contrast-media administration, but the
thresholds used and the acceptable time between the
determined SCr value and administration of contrast media
to perform the radiology examination differs among
radiology departments.
Risk-factor questionnaire
For outpatient radiological studies where renal function data
are unavailable, a simple survey or questionnaire may be
used to identify outpatients at higher risk for AKI in whom
appropriate precautions should be taken.
Choyke et al.411 (Figure 13) used a questionnaire and
could identify a high proportion of patients with normal SCr
concentrations, and reduced by 67% the number of patients
in whom SCr measurement was necessary before imaging
studies.
The European Society of Urogenital Radiology386 recom-
mends a risk-factor analysis based on the Choyke ques-
tionnaire to identify patients with a higher risk of abnormal
renal function. The CI-AKI Consensus Working Panel410
considered that a survey or questionnaire may be a useful
guide for identifying patients at higher risk for CI-AKI
compared to the general population.
Urinary protein screening
The CI-AKI Consensus Working Panel also supported the
use of dipstick testing for urine protein as a rapid screen to
identify patients who can undergo studies requiring contrast
media without SCr measurement.410 Of 310 patients with a
negative urine protein test and no history of diseases poten-
tially associated with renal impairment, none had a SCr
level 42.0mg/dl (4177 mmol/l), and only 1% had a level
41.7mg/dl (4150 mmol/l).
Thus, the Work Group recommends that, when a recent
SCr is not available, a simple questionnaire or a dipstick
testing for urine protein may be useful for identifying
pre-existing kidney disease. Risk stratification hinges on age,
baseline kidney function, other comorbidities, and other risk
factors.
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Other risk factors of CI-AKI
Besides pre-existing kidney disease with renal function
impairment, other risk factors for developing CI-AKI
include diabetes, hypertension, CHF, advanced age, volume
depletion, hemodynamic instability, use of concurrent
nephrotoxic medications, and large volume or high osmol-
ality of the contrast agent.408,412 Although there is doubt that
diabetes by itself is an independent risk factor, in a patient
with CKD it acts as a risk multiplier.398 Metabolic syndrome,
prediabetes, and hyperuricemia have been identified as
new risk factors for CI-AKI, while the use of ACE-I and
angiotensin-receptor blockers (ARB), renal transplantation,
diabetes mellitus with normal renal function, low-osmolar
contrast media, multiple myeloma, female gender, and
cirrhosis have been classified as conflicting risk factors for
CI-AKI.413 There are conflicting data on the impact of ACE-I
or ARB but, overall, there is currently insufficient evidence to
recommend discontinuation of these medications prior to
contrast-media administration.
When possible, the administration of contrast media
should be delayed in patients with circulatory collapse or
CHF until their hemodynamic status is corrected. Repeated
exposure should be delayed for 48 hours in patients
without risk factors for CI-AKI, and for 72 hours in those
with diabetes mellitus or pre-existing chronic renal dysfunc-
tion. If acute renal dysfunction develops after contrast-media
administration, repeated exposure should preferably be
delayed until the SCr level has returned to baseline levels.414
Concurrent nephrotoxic medication—including, in
particular, NSAIDs, aminoglycosides, amphotericin B, high
doses of loop diuretics, and antiviral drugs like acyclovir
and foscarnet—should preferably be stopped. A recent
study using a so-called forced euvolemic diuresis protocol
including mannitol and furosemide led to a signi-
ficantly increased risk of CI-AKI.415 It can be advised that
such strategy should be abandoned, and that furose-
mide therapy should preferably be stopped before angio-
graphy.
In the past 3 months have you been told there may have been a change in your kidney function?  Y/N 
In the past 3 months have you been on any medications? Please list: 
Have you used any over-the-counter pain relievers within the last 10 days? Y/N  Please list: 
In the past 3 months have you had any surgery?  Y/N 
Describe: 
Do you feel dry or thirsty? Y/N 
Circle one 
*Have you ever been told you have kidney disease of any type?
Please describe:
Y N
*Have you had kidney surgery? Y N
*Do you have diabetes?
Do you use insulin?
Do you use metformin or glucophage?
Y
Y
Y
N
N
N
*Do you have hypertension, heart disease, or vascular disease? Y N
*Do you have gout? Y N
Do you have multiple myleoma? Y N
Have you ever had x-ray contrast media (dye) for CT, angiography, or IVP?
Have you had contrast media within the last 3 days? 
Do you have any allergies to x-ray contrast media (dye)?
Please describe:
Y
Y
Y
N
N
N
Have you received pretreatment with medication for this study? Y N
Do you have any allergies or asthma? Please describe: Y N
Figure 13 | Sample questionnaire. Asterisks denote questions with the highest association with abnormal renal function. Adapted from
Choyke PL, Cady J, DePollar SL et al. Determination of serum creatinine prior to iodinated contrast media: is it necessary in all patients?
Tech Urol 1998; 4: 65–69 with permission.411
Table 15 | CI-AKI risk-scoring model for percutaneous
coronary intervention
Risk factors Integer score (calculate)
Hypotension 5
IABP 5
CHF 5
Age 475 years 4
Anemia 3
Diabetes 3
Contrast-media volume 1 per 100ml
SCr 41.5mg/dl (4132.6mmol/l) 4
or
eGFR o60ml/min per 1.73 m2 2 for 40–60
4 for 20–39
6 for o20
Note: Low risk: cumulative score o5; high risk: cumulative score 416.
CHF, congestive heart failure; eGFR, estimated glomerular filtration rate; IABP, intra-
aortic balloon pump; SCr, serum creatinine. Reprinted from Mehran R, Aymong ED,
Nikolsky E et al. A simple risk score for prediction of contrast-induced nephropathy
after percutaneous coronary intervention: development and initial validation. J Am
Coll Cardiol 2004; 44: 1393–1399 et al.,418 copyright 2004, with permission from
American College of Cardiology Foundation; accessed http://content.onlinejacc.org/
cgi/content/full/44/7/1393
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Risk models of CI-AKI
Most risk factors for CI-AKI can be detected by
history-taking and physical examination, and the risk rises
exponentially with the number of risk factors present.416
Validated risk-prediction models using patient and proce-
dural risk factors to assess for CI-AKI have been developed
for patients undergoing percutaneous coronary inter-
vention.417,418 For example, the Mehran risk model418 is
given in Table 15. The overall occurrence of CI-AKI in the
development set of the score was 13.1% (range 7.5% to
57.3% for a low [p5] and high [X16] risk score,
respectively); the rate of CI-AKI increased exponentially
with increasing risk score. In the validation dataset, the
increasing risk score was again strongly associated with
CI-AKI (range 8.4% to 55.9% for the low and high risk score,
respectively). These models can help in counseling about the
risks of the procedure, selecting prophylactic interventions,
and can also be used to characterize patients in studies of
CI-AKI.
4.2.2: Consider alternative imaging methods in patients
at increased risk for CI-AKI. (Not Graded)
RATIONALE
The selection and advantages and disadvantages of non-
iodinated contrast media are beyond the scope of these
guidelines. Detailed discussions of all these techniques can
be found in radiology textbooks and the radiology litera-
ture. The Work Group suggests that, in patients at increased
risk for CI-AKI, the risks and benefits of iodinated
contrast-media administration should be discussed with the
radiologist.
Because of the great relevance for the nephrologist,
radiologist, and cardiologist of the side-effects of Gd chelates
used in magnetic resonance imaging (MRI), a short overview
of their nephrotoxicity is given here.
Nephrotoxicity of Gd chelates
Gd chelates are widely used as MRI contrast agents, and
are considered to have a good overall safety profile. Early
on, phase III trials and small studies in low-risk patients
suggested a benign renal profile; however, more recent
studies raised the possibility of nephrotoxicity, although
it is not clear whether it approaches the incidence of
AKI associated with iodine-containing contrast media.
Gd-related AKI appears to be a risk in patients with advanced
kidney disease, especially those with diabetic nephro-
pathy.419,420 Perazella et al.420 have summarized studies
showing Gd-induced nephrotoxic AKI compared to
CI-AKI.421–425 Studies in patients with underlying kidney
disease demonstrate the importance of renal clearance in
determining the pharmacokinetic profile of Gd chelates.426
More details on the pharmacokinetics of Gd chelates and
their dialyzability are provided in Appendix E.
Nephrogenic systemic fibrosis (NSF)
The risk of developing NSF with Gd, particularly in patients
with severe AKI and CKD, is reviewed in detail in Appendix E.
It should be noted here that the European Medicines
Agency stated a contraindication for use of gadodiamide in
patients with a GFR o30ml/min per 1.73m2, and issued a
warning for its use in patients who have a GFR between 30
and 60ml/min per 1.73 m2 (EMEA Public assessment report.
http://www.esur.org/fileadmin/NSF/Public_Assessment_Report_
NSF_Gadolinium_26_June_2007.pdf; last accessed January 5,
2012). The US FDA requested that vendors add warnings
about the risk for developing NSF to the full prescri-
bing information on the packaging for all Gd-containing
contrast agents (gadopentetate dimeglumine, gadodiamide,
gadoversetamide, gadoteridol, gadobenate dimeglumine).427
New labeling describes the risk for NSF following expo-
sure to Gd in patients with a GFR o30ml/min per
1.73 m2 and in patients with AKI of any severity due to
hepato-renal syndrome or in the perioperative liver trans-
plantation period. Additional recommendations were
recently proposed by Perazella420 and were endorsed by the
Work Group:
(a) Use of a macrocyclic chelate (gadoteridol in the USA),
is preferred over linear chelates. The risk associated
with the various Gd-containing agents is likely
different. Gadodiamide, the linear nonionic chelate–-
based formulation, maintains the highest risk on the
basis of epidemiologic data and animal studies.
Gadopentetate, the linear ionic chelate–based product
probably has a medium risk, less than the linear
nonionic chelates but more than the macrocyclic
chelates. Gadoteridol, the only FDA-approved macro-
cyclic chelate, maintains less risk. Clearly, high dosages
and large cumulative dosages of all these agents will
increase risk for NSF.
(b) Demonstration of significant quantities of insoluble
Gd in the skin of NSF patients, months after expo-
sure to Gd-based contrast material and after exten-
sive tissue processing, suggests that Gd might have
undergone transmetallation in vivo. Supporting the
importance of transmetallation, all NSF cases reported
before 2009 have been associated with linear MRI
contrast agents (for a review, see Kay428) that have
inferior thermodynamic stability and a kinetic or
conditional stability that favors transmetallation. How-
ever, a recent case of NSF in a dialysis patient after
exposure to a macrocyclic chelate has been described,429
and at least two additional cases are known.430
(c) Use the lowest dosage of the agent possible to achieve
the image.
(d) Avoid repeat exposures with Gd.
(e) Consider performing IHD after the exposure (and
the next 2 days) in patients who are already main-
tained on IHD, recognizing that there are no data
that support prevention of NSF with this modality.
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This recommendation is based on the pharmaco-
kinetics of Gd and the theoretical benefit of removing
it with IHD (495% plasma clearance). PD clears these
agents rather poorly.
SUPPLEMENTARY MATERIAL
Appendix E: Risks with Gadolinium-Based Contrast Agents.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/AKI.php
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Chapter 4.3: Nonpharmacological prevention
strategies of CI-AKI
There have been a large number of strategies/agents evaluated
to prevent CI-AKI. Sterling et al.431 have recently summa-
rized most of these strategies and classified them as having
either definitive, possible, or doubtful value. From the many
strategies, these authors only retain parenteral volume
expansion, minimizing contrast-media volume, use of low-
osmolar and iso-osmolar contrast media, and administration
of non-iodinated contrast media as strategies with definitive
value. A recent comprehensive meta-analysis by Kelly
et al.432—including RCTs that administered NAC, theophyl-
line, fenoldopam, dopamine, iloprost, statins, furosemide,
or mannitol, and covering studies up to November 2006—
provides an excellent overview.
DOSE/VOLUME OF CONTRAST-MEDIA ADMINISTRATION
4.3.1: Use the lowest possible dose of contrast medium in
patients at risk for CI-AKI. (Not Graded)
RATIONALE
The correlation between the volume of contrast media
administered and the risk of CI-AKI has been recognized. 433
In the vast majority of papers dealing with CI-AKI after
coronary procedures, contrast-media doses are only ex-
pressed in volumes. The Work Group feels that such
expression can be misleading, since commercially available
contrast-media concentrations range from 140 to 400
milligrams of iodine per milliliter, a difference with almost
a factor of 3. The Work Group recommends, therefore, that
the dose of contrast medium should be better expressed in
relation to both volume and concentration, e.g., grams
iodine, which also directly relates to the diagnostic capacity,
the primary purpose of the contrast medium. Such ‘‘double’’
expression would also facilitate the comparison between
different studies on epidemiology and prognosis of CI-AKI.
It is well known that, when measuring the plasma
clearance of a GFR marker (e.g., with the contrast medium
iohexol), the AUC is directly related to the dose of iohexol
and inversely related to the GFR. Thus, by mathematically
estimating the AUC and knowing the injected iodine
dose, the GFR can be calculated by dose C AUC. Thus,
AUC¼ dose C GFR, and AUC is directly related to the
systemic exposure of a drug, including the contrast medium,
which, in turn, is mostly correlated with its efficacy and
toxicity.434 An interesting experimental study435 investigated
the correlation between the calculated dose to CrCl ratio and
the experimentally measured AUC for the contrast agent
iodixanol. The experimentally determined AUC data correlated
highly with the dose:CrCl ratio. This ratio could thus be a rapid
and accurate way to estimate AUC for an iodinated contrast
medium, without the need for multiple blood samples.
A recent study by Nyman et al.436 in patients undergoing
coronary angioplasty calculated the probability of CI-AKI
(SCr rise 40.5mg/dl [444.2 mmol/l] or oliguria/anuria) at
various eGFR levels based on g-I (grams iodine)/eGFR ratios
of 1:2, 1:1, 2:1, and 3:1. At a ratio o1, the risk of CI-AKI
was 3%, while it was 25% at a ratio X1. This, and other
preliminary studies, indicate that a g-I/GFR ratioo1 may be
relatively safe in a patient without multiple risk factors.436–438
Finally, the association between absolute and body weight-
and SCr-adjusted contrast-media volume, CI-AKI incidence
(X25% SCr increase), and clinical outcome was prospec-
tively investigated in patients with acute MI.439 For each
patient, the maximum contrast-medium dose was calculated
according to the formula (5 body weight [kg])C SCr, and
the contrast-medium ratio—defined as the ratio between the
contrast-medium volume administered and the maximum
dose calculated—was assessed. Development of CI-AKI was
associated with both contrast-medium volume and ratio.
Additional radiological measures to reduce CI-AKI can be
found in Table 16.
Route of administration of contrast media
The risk of CI-AKI appears to be greater after arterial
compared to venous administration of contrast media.
Indeed, in the rare studies where an appropriate control
group without contrast media was included, no significant
difference was observed in the rate of CI-AKI between the
patients who received i.v. iodinated contrast media and the
control subjects who did not.440–442 Thus, the risk of CI-AKI
with i.v. contrast medium is probably very low. CI-AKI
reportedly occurs after i.v. contrast-medium injection for CT
in only 4% of patients with CKD.443 Katzberg and Lamba444
summarized the six studies on CI-AKI after i.v. contrast-
medium administration in patients at risk and all suffering
from moderate CKD. The overall incidence of CI-AKI in
these studies, using the current generation of low-osmolar
contrast media, was about 5%.
Given the logistic challenges in the outpatient setting, the
use of specific prophylactic measures prior to administration
of i.v. contrast media could be limited to those subjects
who are at higher levels of baseline risk than they would be
when an i.a. procedure was planned.445 This conclusion, may
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however, be too optimistic when applied to critically ill
patients undergoing emergency CT scans.395
The majority of the literature covering CI-AKI and its
prevention involves i.a. iodinated contrast-medium admin-
istration.445,446 The higher risk of CI-AKI after i.a. admin-
istration is probably due to the more direct exposure of the
kidneys to contrast media,447 or to the fact that, in general,
i.a. contrast-media examinations are performed in patients
who carry a higher risk.
RESEARCH RECOMMENDATIONS
K Randomized trials should explore whether there is need
for discontinuation of ACE-I and/or ARBs in patients at
risk for CI-AKI.
K Additional studies are needed to better determine the
exact relationship between the dose of contrast media and
the risk for CI-AKI.
SELECTION OF A CONTRAST AGENT
4.3.2: We recommend using either iso-osmolar or low-
osmolar iodinated contrast media, rather than
high-osmolar iodinated contrast media in patients
at increased risk of CI-AKI. (1B)
RATIONALE
This recommendation is supported by the summary tables of
the different RCTs and on the evidence profile tables (Suppl
Tables 19–21).
High-osmolar vs. iso-osmolar or low-osmolar contrast media
The recommendation to avoid high-osmolar contrast media
is based on older literature, since recent RCTs comparing
high- vs. low- and iso-osmolar iodine-based contrast media
are not available. In addition, high-osmolar contrast media
have virtually been abandoned in modern radiological units.
Both the review of Goldfarb et al.,448 and the meta-analysis of
Barrett and Carlisle combining 24 randomized studies449
suggest that the risk of CI-AKI is similarly low with high-
osmolar and low-osmolar agents among otherwise stable
patients with normal renal function, but that in contrast to
high-osmolar contrast media, low-osmolar contrast media
are less nephrotoxic in patients with pre-existing kidney
function impairment.
Low-osmolar vs. iso-osmolar contrast media
The present hotly debated question is whether iso-osmolar
contrast media are safer than low-osmolar contrast media in
high-risk patients. This question has been the subject of a
number of randomized trials as well as systematic reviews
and meta-analyses (Suppl Tables 19–21).
We separated studies meeting our inclusion criteria (see
Chapter 1.2) into those administering i.a. or i.v. contrast
media. We used the general definitions of CI-AKI provided in
the studies (an increase in SCr by 425% or 0.5mg/dl
[44.2 mmol/l]) occurring within 72 hours after contrast-
medium administration, in the absence of an alternative
etiology for the decrease in kidney function.
Table 16 | Additional radiological measures to reduce CI-AKI
Some CT strategies in patients at risk of CI-AKI
K Perform CT, when possible, without contrast media; scrutinize the examination and discuss with the referral physician-surgeon before deciding on
the need for contrast media.
K Dosing per kilogram body weight to reduce the amount of contrast media is needed in thin patients.
K Adapt injection duration to scan duration when performing CT-angiography, so that the injection is not still running when the scan is finished.
K Use a saline chaser to decrease the amount of contrast media, by using the contrast medium that otherwise would remain in the dead space of the
arm veins; this may save 10–20ml of contrast media.
K Use 80 kVp; contrast-medium dose may be reduced by a factor of 1.5–1.7 compared to the dose used at 120 kVp since iodine attenuation increases,
and combine with increased tube loading (mAs) to maintain signal-to-noise ratio.
K Further reduction of contrast media may be instituted in patients with known decreased cardiac output (not unusual in patients with renal
impairment) undergoing CT-angiographic studies.
Some angiographic strategies in patients at risk of CI-AKI
K Use biplane when appropriate.
K Avoid test injections; the same amount may be enough for a diagnostic digital-subtraction angiography run.
K Scrutinize each series before performing the next; avoid unnecessary projections.
K Decrease kilovoltage in a thin patient; a lower iodine concentration may be used.
K Assess the physiologic significance of a stenosis by measurement of translesional pressure gradient and fractional flow reserve, a technique well
accepted and validated for the coronary circulation. For different arterial beds, perform manometry of a questionable stenosis instead of multiple
projections.
K Avoid ventriculography: echocardiography (and ‘‘echo contrast’’) is always a reasonable alternative.
K Use plasma isotonic contrast-media concentrations for renal artery injections.
K When renal artery stenosis is suspected, map the origin of major renal arteries with noninvasive procedures (e.g., CT without contrast media) for
proper initial renal angiographic projections to avoid unnecessary runs, or perform primary manometry.
K CO2 may be used as contrast medium in venous examinations and below the diaphragm for arterial examinations or alternatively use iodinated
contrast media with the same contrast effect, i.e., about 40mg iodine per milliliter.
K Since the contrast effect of 0.5M Gd-contrast media has been regarded as diagnostic by many investigators (coronary, renal, aortofemoral
arteriography, etc.), iodinated contrast media may be diluted to the same density, i.e., about 75mg iodine per milliliter.
K Use selective or superselective catheterizations when appropriate, e.g., ‘‘single leg run-off’’.
K Reduce aortic flow and amount of contrast medium by temporal occlusion of femoral arteries with tourniquets when performing aortography.
Gd, gadolinium; kVp, peak kilovoltage.
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In total, 14 RCTs fulfilling the search criteria were found.
Ten RCTs were found with i.a. and four RCTs with i.v.
injection, respectively (Suppl Tables 19–21). There is only
moderate quality of evidence and overall, no benefit—or, at
least, no consistent benefit—was found of nonionic iso-
osmolar (iodixanol) contrast media compared to low-
osmolar ionic or nonionic contrast media. In eight studies
comparing contrast media given i.a.401,450–456 some showed
superiority of iso-osmolar contrast media (iodixanol),
compared to iohexol450 and iopromide.455 There was no
difference when iodixanol was compared to iopamidol,401,452
iopromide,451,453 and ioversal.456
The most recent prospective, multicenter, randomized,
double-blind study compared the renal effects of iodixanol to
the nonionic, low-osmolar agent iopamidol, in 526 subjects
with CKD and diabetes mellitus undergoing diagnostic
and/or therapeutic coronary angiography.454 The overall
CI-AKI incidence was 10.5% (11.2% % in the iodixanol
arm and 9.8% in the iopamidol arm, NS). The volume of
contrast medium, volume of saline administered, frequency
of coronary interventional procedures, and severity of
baseline kidney disease and of diabetes mellitus were similar
between treatments.
Finally, a recent meta-analysis457 (Figure 14) analyzed
studies comparing iodixanol with low-osmolar contrast
media. The pooled RR was 0.68 (95% CI 0.46–1.01;
P¼ 0.06). In studies that included patients with normal
renal function after i.a. contrast-media administration, the
RR was 0.82 (95% CI 0.45–1.51; P¼ 0.53). In the studies that
included only patients with decreased kidney function after
i.a. contrast-media administration, the RR was 0.59 (95% CI
0.33–1.07; P¼ 0.08). However, in all three studies in which
iohexol was the low-osmolar contrast medium used, the risk
of CI-AKI was significantly lower with iodixanol (RR 0.38;
95% CI 0.21–0.68; Po0.01). In contrast, the risk of CI-AKI
did not significantly differ in the two studies in which
iodixanol was compared to other low-osmolar contrast
agents (RR 0.95; 95% CI 0.50–1.78; P¼ 0.86). Iodixanol is
thus not associated with a significantly reduced risk of CI-
AKI compared to the low-osmolar contrast media pooled
together. However, in patients with decreased kidney
function, iodixanol is associated with a reduced risk of CI-
AKI compared to iohexol.
The clinical heterogeneity between all these studies, as far
as basal kidney function and prevalence of diabetes mellitus
are concerned, hampers the ability to compare the results
across studies, but can widen the applicability of consistent
findings across different risk groups provided the mechan-
isms of contrast-induced nephrotoxicity are the same. One
should note, also, that in all these studies different definitions
of CI-AKI have been used and that the timing of SCr
measurements after contrast-media injection was not uni-
form. It has been shown that different time-points for the
measurement of CI-AKI can give different results.458 One
may expect that those studies with a standardized and
simultaneous measurement of renal function between the
two arms are probably the most conclusive. Finally, different
types and amounts of volume expansion and different
pharmacological preventive strategies have been used
throughout the studies, making conclusive comparisons
virtually impossible.
i.a. Iodixanol vs. ioxaglate
Two studies fulfilled our inclusion criteria; one study459
showed a superiority of iodixanol vs. ioxaglate, but this was
not confirmed in the study by Mehran et al.,460 who found no
difference between these two contrast agents. Although
overall the number of patients is substantial, there is
heterogeneity among the comparators with which iodixanol
has been compared. In addition, the cost of iodixanol is
probably higher than the cost of most of the low-osmolar
contrast agents. No studies comparing a possible difference
Figure 14 |Risk for contrast-induced nephropathy. (a) Iodixanol vs. iohexol and risk for contrast-induced nephropathy; (b) iodixanol vs.
nonionic low-osmolar contrast media other than iohexol and risk for contrast-induced nephropathy. Reprinted from Heinrich MC, Haberle L,
Muller V et al. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low osmolar contrast media: meta-analysis of randomized
controlled trials. Radiology 2009; 250: 68–86 with permission, copyright 2009, from Radiological Society of North America457; accessed
http://radiology.rsna.org/content/250/1/68.long
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among low-osmolar contrast media have been performed.
Based on evidence profiles (Suppl Tables 19 and 20) and
the most recent meta-analysis457 (Figure 14) of the studies
comparing i.a. administration of iso- vs. low-osmolar
contrast media, the Work Group found no evidence to
recommend a preference for either type of agent.
i.v. Administration
There are four studies following i.v. injections fulfilling our
inclusion criteria: Barrett et al.,443 Kuhn et al.,461 Thomsen
et al.,462 and Nguyen et al.463 The overall conclusion, based
on the evidence profile summarized in Suppl Table 20
comparing i.v. iso- vs. low-osmolar contrast media, is that
there is no benefit for the nonionic iso-osmolar agent
(iodixanol); the overall quality of the evidence is moderate.
This conclusion is supported by the above-mentioned recent
meta-analysis457 which, in seven studies comparing i.v.
contrast-media administration with iodixanol vs. low-osmolar
contrast media, showed no statistically significant difference
for CI-AKI (RR 1.08; 95% CI 0.62–1.89; P¼ 0.79). Subgroup
analysis did not show superiority of any agent in studies of
individuals with normal kidney function (RR 1.12; 95% CI
0.35–3.65; P¼ 0.85) or in studies of individuals with reduced
kidney function (RR 1.07; 95% CI 0.56–2.02; P¼ 0.84).
In head-to-head comparisons with different low-osmolar
agents, iodixanol has been shown to be superior to
iopromide, but not to iopamidol and iomeprol. It is,
however, difficult to determine whether this is simply due
to spurious findings in a smaller number of comparisons, or
due to true differences between low-osmolar agents. Until
better head-to-head comparative studies among the different
contrast media agents are available, the Work Group is
unable to draw definite conclusions on the selection of
iso-osmolar vs. low-osmolar contrast media.
RESEARCH RECOMMENDATION
K Additional studies with head-to-head comparisons
among the different contrast media should be performed
in order to draw definite conclusions on the selection
of iso-osmolar vs. low-osmolar contrast media. A more
uniform definition of CI-AKI, as suggested in this
guideline, should be used as the end-point.
SUPPLEMENTARY MATERIAL
Supplementary Table 19: Evidence profile of RCTs examining the effect
of intrarterial isosmolar vs. low osmolar contrast agent on the
prevention of CI-AKI.
Supplementary Table 20: Evidence profile of RCTs examining the effect
of intravenous isosmolar vs. low osmolar contrast agent on the
prevention of CI-AKI.
Supplementary Table 21: Summary table of RCTs examining the effect of
isosmolar vs. low osmolar contrast agent on the prevention of CI-AKI.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/AKI.php
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Chapter 4.4: Pharmacological prevention strategies
of CI-AKI
FLUID ADMINISTRATION
Extracellular volume expansion at the time of radiocontrast-
media administration may serve to counteract both the
intrarenal hemodynamic alterations and the direct tubulo-
toxic effects that play a role in the pathophysiology of CI-
AKI. Neurohumoral effects of volume expansion that may
attenuate radiocontrast-induced medullary hypoxia include
suppression of vasopressin as well as inhibition of the renin-
angiotensin axis; but an increased synthesis of vasodilatory
renal prostaglandins may also play a role.464
Volume expansion may also directly reduce cellular
damage by dilution of the contrast medium, particularly in
the medullary tubular segments. Likewise, an effect of
radiocontrast media to increase tubular fluid viscosity may
be diminished by intravascular volume expansion.465 It is
important to note that these potentially attenuating effects of
volume expansion are speculative, and the precise mechan-
isms by which volume expansion protects against CI-AKI
remain unknown.
4.4.1: We recommend i.v. volume expansion with either
isotonic sodium chloride or sodium bicarbonate
solutions, rather than no i.v. volume expansion, in
patients at increased risk for CI-AKI. (1A)
RATIONALE
Despite the recognition of volume depletion as an important
risk factor for AKI, there are no RCTs that have directly
evaluated the role of fluids vs. placebo in the prevention of
AKI. However, RCTs have compared different fluids and have
combined fluids with other interventions.191 Furthermore,
comparisons between outcomes seen in these trials191 and
historical untreated control subjects466 suggest a large benefit
from fluids. In particular, volume expansion and treatment of
dehydration are well-established interventions in the preven-
tion of CI-AKI. A recent propensity analysis, however, noted
that strategies to prevent CI-AKI are implemented rather
nonuniformly.467 Pre– and post–contrast-media administra-
tion i.v. fluids were given to only 264 of 660 study patients
(40.0%), more commonly with coronary angiography than
with CT (91.2% vs. 16.6%). Other preventive measures, such
as administration of NAC or discontinuation of NSAIDs,
were equally rarely applied. Only 39.2% of patients received
NAC, while only 6.8% of patients were instructed to
discontinue NSAIDs. In a propensity analysis, the use of
i.v. fluids was associated with a reduced rate of CI-AKI. The
incidence of CI-AKI was lowest following CT (range,
0.0–10.9%) and was highest following noncoronary angio-
graphy (range, 1.9–34.0%).
The fluids that have been tested in the prevention of
CI-AKI are hypotonic saline (0.45%), isotonic saline (0.9%)
and isotonic sodium bicarbonate. The interpretation of all
these studies is hampered by the fact that not all other risk
factors (susceptibilities) for CI-AKI were excluded or
considered in every study (i.e., age of the patient, presence
of CKD and/or diabetes prior to contrast-media administra-
tion, type and dose of contrast agent, associated therapy with
NAC, and other risk factors [see Chapter 2.2]).
There is no clear evidence from the literature to guide the
choice of the optimal rate and duration of fluid infusion in
CI-AKI prevention, but most studies suggest that the fluids
should be started at least 1 h before and continued for 3–6
hours after contrast-media administration. A ‘‘good’’ urine
output (4150ml/h) in the 6 hours after the radiological
procedure has been associated with reduced rates of AKI in
one study.468 Since not all of i.v. administered isotonic
crystalloid remains in the vascular space, in order to achieve
a urine flow rate of at least 150ml/h, X1.0–1.5ml/kg/h of
i.v. fluid has to be administered for 3–12 hours before and
6–12 hours after contrast-media exposure.
Mueller et al.469 found that i.v. 0.9% saline solution,
compared to 0.45% saline solution in dextrose, in 1620
patients undergoing coronary angiography significantly
reduced CI-AKI. The sustained administration of isotonic
saline before and after radiocontrast injection seems, thus,
to be more protective than equivalent volumes of hypotonic
saline.464 Although the mechanism by which sodium
bicarbonate, beyond its volume-expanding effects, might
further reduce CI-AKI remains poorly defined, it has been
postulated that sodium bicarbonate infusion may decrease
generation of free radicals mediated by the Haber-Weiss
reaction by increasing tubular pH. The Haber-Weiss reaction
is most active at lower pH levels.470 Sodium bicarbonate
infusion may also scavenge the potent oxidant peroxynitrate,
produced via a nitric oxide–mediated pathway.471 Reactive
oxygen species activate cytokine-induced inflammatory
mediators, resulting in damage to proximal tubular cells,472
and it is likely that the activation of these mediators is
influenced by tissue hypoxia and intracellular medullary
acidosis.473
It is worth noting that, compared to i.v. bicarbonate, the
combination of oral azetazolamide inducing an alkaline
urine, plus i.v. saline, was more effective for the prevention of
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CI-AKI than saline alone, in a relatively small study in
children with stable chronic renal failure (CRF).474 It could
also be hypothesized that sodium bicarbonate has a stronger
impact in lowering the intratubular viscosity caused by the
contrast medium, compared to isotonic saline, because it
causes less tubular sodium reabsorption than saline.
Sodium bicarbonate solutions have been tested in the
prevention of CI-AKI in comparison with isotonic saline,
either with or without NAC. A number of systematic reviews
on the role of sodium bicarbonate compared to isotonic
saline in the prevention of CI-AKI are available.475–481
The most recent and probably the most complete
systematic review481 analyzed MEDLINE, PubMed, EMBASE,
and the Cochrane Central Register of Controlled Trials from
1950 to December 2008; conference proceedings; and
ClinicalTrials.gov, without language restriction (Figure 15).
This systematic review included RCTs of i.v. sodium
bicarbonate that prespecified the outcome of CI-AKI as a
25% increase in baseline SCr concentration or an absolute
increase of 0.5mg/dl (44.2 mmol/l) after contrast-media
administration. Twenty-three published and unpublished
trials with information on 3563 patients and 396 CI-AKI
events were included. The pooled RR was 0.62 (95% CI
0.45–0.86), with evidence of significant heterogeneity across
studies. Some heterogeneity was due to the difference in the
estimates between published and unpublished studies: RR
0.43 (95% CI 0.25–0.75) vs. 0.78 (95% CI 0.52–1.17),
respectively. Meta-regression showed that small, poor-quality
studies that assessed outcomes soon after contrast-media
administration were more likely to suggest the benefit of
bicarbonate (Po0.05 for all). No clear effects of treatment on
the risk for dialysis, heart failure, and total mortality were
identified.
Suppl Tables 22 and 23 summarize the evidence from
RCTs where isotonic bicarbonate was compared to isotonic
saline alone, without concomitant other ‘‘preventive’’ inter-
ventions. In all studies, a minimum of 50 patients in both
arms and publication as full paper were required for
inclusion in the tables. Only three studies directly compared
isotonic bicarbonate to isotonic saline.470,482,483 In a fourth
study by Brar et al.,484 NAC was included in 47% and 46% of
the patients in both arms of the study (bicarbonate vs.
saline), respectively. The first study was a small single-center
RCT470 enrolling 119 patients with stable SCr of at least
1.1mg/dl (97.2 mmol/l), randomized to either infusion of
isotonic saline or isotonic sodium bicarbonate before and
after contrast-media administration. CI-AKI (defined as an
increase of 25% in SCr from baseline within 48 hours)
Figure 15 |Bicarbonate vs. saline and risk of CI-AKI. Reprinted from Zoungas S, Ninomiya T, Huxley R et al. Systematic review: sodium
bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med 2009; 151: 631–638 with permission
from American College of Physicians481; accessed http://www.annals.org/content/151/9/631.full
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developed in 1.7% in the bicarbonate group, compared to
13.6% in the saline solution group.
Ozcan et al.483 included three prophylactic regimens:
infusion of sodium bicarbonate, sodium chloride, and sodium
chloride plus oral NAC (600mg b.i.d.). The incidence of
CI-AKI, defined as an increase in SCr level425% or 0.5mg/dl
(44.2mmol/l) after 48 hours was significantly lower in the
sodium bicarbonate group (4.5%) compared to sodium
chloride alone (13.6%, P¼ 0.036). After adjusting for the
Mehran nephropathy risk score, the risk of CI-AKI signifi-
cantly reduced with sodium bicarbonate compared to sodium
chloride alone (adjusted risk ratio 0.29; P¼ 0.043).
By contrast, Adolph et al.482 did not find differences in CI-
AKI between the two fluid regimens on day 1 after
angiography; even on day 2, most parameters were similar
in both groups. In none of the above-mentioned studies was
there need for RRT.
Finally, a recent but retrospective study485 defined CI-AKI
as an increase in SCr X25% within 48 hours of receiving
contrast media, and compared sodium bicarbonate to
normal saline in patients exposed to cardiac angiography.
One group of patients (n¼ 89) received prophylactic
bicarbonate; a second group, normal saline (n¼ 98). The
patients in the bicarbonate group had more severe renal
disease with higher baseline SCr (1.58 ± 0.5mg/dl; 140 ±
44.2 mmol/l) vs. (1.28 ± 0.3mg/dl; 113 ± 26.5 mmol/l),
P¼ 0.001 and a lower eGFR, compared to the normal saline
group. After contrast-media exposure, there was significant
drop in eGFR (6.4%) and increase in SCr (11.3%) in the
normal saline group and no significant change in the
bicarbonate group. Three patients (3.4%) in the bicarbonate
group, as opposed to 14 patients (14.3%) in the normal saline
group, developed CI-AKI (P¼ 0.011). Two patients in the
normal saline group and none in the bicarbonate group
needed dialysis. This study suggests that the use of i.v.
sodium bicarbonate is more effective than normal saline in
preventing CI-AKI.
Three studies compared bicarbonate and saline solutions
associated with the administration of NAC in both study
arms.486–488 Recio-Mayoral et al.488 conducted a prospective
single-center RCT in 111 consecutive patients with acute
coronary syndrome undergoing emergency angioplasty. One
group of patients received an infusion of sodium bicarbonate
plus NAC started just before contrast-media injection and
continued for 12 hours after angioplasty. The second
(control) group received the standard fluid protocol consist-
ing of i.v. isotonic saline for 12 hours after angioplasty. In
both groups, two doses of oral NAC were administered the
next day. A SCr concentration 40.5mg/dl (444.2 mmol/l)
from baseline after emergency angioplasty was observed in
1.8% in the bicarbonate group and in 21.8% of the saline
group. Mortality and need for RRT were not significantly
different between both groups. Briguori et al.486 randomized
326 CKD patients (SCr X2mg/dl [X177 mmol/l] and/or
eGFR o40ml/min per 1.73 m2), and referred for coronary
and/or peripheral procedures to three different protocols:
prophylactic administration of 0.9% saline infusion plus
NAC (n¼ 111), sodium bicarbonate infusion plus NAC
(n¼ 108), and 0.9% saline plus ascorbic acid plus NAC
(n¼ 107). CI-AKI was defined as an increase ofX25% in the
SCr concentration 48 hours after the procedure. CI-AKI
occurred in 9.9% of the saline plus NAC group, in 1.9% of
the bicarbonate/NAC group (P¼ 0.019 vs. saline plus NAC
group), and in 10.3% of the saline plus ascorbic acid plus
NAC group (P¼ 1.00 vs. saline plus NAC group). There was
no difference in mortality nor in need for RRT among the
different groups. While these two studies suggest that
isotonic bicarbonate may provide greater benefit than
isotonic saline, either in association with NAC or not, neither
study can be considered conclusive.
Maioli et al.487 prospectively compared the efficacy of
sodium bicarbonate vs. isotonic saline in addition to NAC in
a larger population of 502 patients with an estimated CrCl
o60ml/min, and undergoing coronary angiography or
intervention. CI-AKI was defined as an absolute increase of
SCrX0.5mg/dl (X44.2 mmol/l) measured within 5 days. CI-
AKI occurred in 10.8%; 10% were treated with sodium
bicarbonate and 11.5% with saline. In patients with CI-AKI,
the mean increase in creatinine was not significantly different
in the two study groups. Based on this last prospective study,
bicarbonate does not seem to be more efficient than saline.
Furthermore, a retrospective cohort study at the Mayo Clinic
assessed the risk of CI-AKI associated with the use of sodium
bicarbonate, NAC, or the combination. Surprisingly, i.v.
sodium bicarbonate was associated with an increased
incidence of CI-AKI.489
While one might take the position that, if in doubt, one
should choose the regimen that is potentially superior, the
Work Group also considered the potential harm. In addition,
isotonic bicarbonate solutions are usually composed by
adding 154ml of 8.4% sodium bicarbonate (i.e., 1mmol/
ml) to 846ml of 5% glucose solution, resulting in a final
sodium and bicarbonate concentration of 154mmol/l each.
Since this mixing of the solution is often done at the bedside
or in the hospital pharmacy, there is the possibility for errors
leading to the infusion of a hypertonic bicarbonate solution.
The potential for harm from dosing errors, and the added
burden from preparation of the bicarbonate solution, has to
be taken into account in clinical practice when making a
choice between using bicarbonate rather than standard
isotonic saline solutions. Taken together, the Work Group
concluded that there is a possible but inconsistent benefit of
bicarbonate solutions based on overall moderate-quality
evidence (Suppl Table 22). As discussed above, the potential
of harm and the additional burden for preparing the
bicarbonate solutions led the Work Group not to express a
preference for or against one solution (isotonic saline or
isotonic bicarbonate). Thus, either can be used for the
prevention of CI-AKI.
4.4.2: We recommend not using oral fluids alone in
patients at increased risk of CI-AKI. (1C)
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RATIONALE
Oral volume expansion may have some benefit, but there is
not enough evidence to show that it is as effective as i.v.
volume expansion.490 One small RCT of 53 patients491 who
underwent nonemergent cardiac catheterization found that
i.v. volume expansion with saline was more effective than
unrestricted oral fluid intake. A more recent trial492 examined
the effects of oral volume intake on renal function in 180
patients with preserved renal function referred for coronary
CT angiography. The patients were divided into two groups:
106 subjects with an increase in SCr after coronary CT
angiography; and 74 without. Significant correlations were
observed between the amount of oral fluid intake and the
percentage changes in SCr as well as the absolute changes in
eGFR. In multiple regression analysis, the amount of oral
fluid intake was the only independent predictor for an
increase in SCr. However, a recent study compared oral fluids
(water with or without bicarbonate) to i.v. fluids (isotonic
saline or bicarbonate) and did not find differences in
incidence of CI-AKI patients with mild CKD. If confirmed
in larger studies, this regimen could offer an equivalent and
more practical approach in preventing a decline in renal
function after contrast exposure, without accruing additional
delay in hospital days or in-hospital mortality.493
ROLE OF NAC IN THE PREVENTION OF CI-AKI
4.4.3: We suggest using oral NAC, together with i.v. iso-
tonic crystalloids, in patients at increased risk of
CI-AKI. (2D)
RATIONALE
NAC—in many, but not all, studies—has been shown to have
a protective effect on CI-AKI when administered before the
onset of renal insult; for a review, see McCullough.494 In
addition, NAC is inexpensive and appears to be safe,
although it may have some detrimental effects on myocardial
and coagulation function.371–373 The ‘‘safety’’ of NAC should
further be amended, particularly when high i.v. doses are
used, as in some of the RCTs in CI-AKI. When prospectively
studied in acetaminophen poisoning, i.v. NAC produced
anaphylactoid reactions in up to 48% of participants.374
Although most of these reactions were mild, at least one
death has been reported in a patient with asthma.375 It should
be noted that the doses used in acetaminophen intoxication
are still much higher than in the ‘‘high doses’’ used in CI-AKI
prevention trials. In a recent review,495 doses of NAC 300mg/
kg i.v. over 21 hours, 980mg/kg i.v. over 48 hours, and
1330mg/kg p.o. over 72 hours were mentioned to have been
all comparably effective at preventing hepatotoxicity in most
uncomplicated early-presenting acute acetaminophen over-
doses. Although a variety of doses of NAC has been
administered in the prevention of CI-AKI, the i.v. ‘‘high
doses’’ used in one study496 are mostly 2 1200mg NAC per
day for 2–3 days, far below the doses used in acetaminophen
intoxication. A meta-analysis497 of studies using high doses
of NAC defined the latter as a daily dose greater than 1200mg
or a single periprocedural dose greater than 600mg
(periprocedural being described as immediately or within 4
hours of the planned contrast exposure). It should also be
remembered that no FDA label is available for NAC as a
preventive drug of AKI.
Suppl Tables 24 and 25 summarize the quite numerous
RCTs where NAC has been compared to placebo on the
impact of patient mortality, need for RRT, or prevention of
CI-AKI. In most of the studies, i.v. fluids, either with isotonic
saline or with isotonic bicarbonate, was used in both arms.
Moreover, the impact of NAC on important ‘‘hard’’ patient
outcomes, such as all-cause mortality, need for RRT, or
doubling of SCr level has only rarely been studied. At present,
there is no current evidence that either oral or i.v. NAC can
alter mortality or need for RRT after contrast-media
administration to patients at risk for CI-AKI. The only study
showing a significant decrease in hospital mortality is the
three-arm study of Marenzi et al.498 in patients undergoing
primary angioplasty. Overall in-hospital mortality was higher
in patients with CI-AKI, defined as a 25% increase in SCr,
than in those without CI-AKI (26 % vs. 1 %; Po0.001).
Thirteen patients (11%) in the control group died, as did five
(4%) in the standard-dose NAC and three (3%) in the high-
dose NAC group (P¼ 0.02). All other studies did not show a
beneficial effect on mortality (Suppl Table 25). Overall, this
evidence was deemed to be of moderate quality and the
possible positive effect on mortality dubious.
The effect of NAC on the incidence of CI-AKI is quite
variable. As is shown in the evidence profile (Suppl Table 24),
the evidence that NAC reduces CI-AKI, as defined in the
different trials, comes from studies with rather heterogeneous
results; most of the studies were of either high or modest
quality. In one study, a protective—even dose-dependent—
effect was observed.498 In that study, the risk for CI-AKI was
reduced by 54.5% in the standard-dose NAC group and by
75.8% in the high-dose NAC group. These findings are in
sharp contrast to many other studies showing no effect and,
in particular, with the large study of Webb et al.,499 which was
terminated early after enrollment of 487 patients because
of a determination of futility by the Data Safety Monitoring
Committee. As mentioned earlier, combination studies of
NAC with bicarbonate administration486 have found a
moderate benefit for this combination, compared to the
combination of NAC-saline.
As recently remarked by Fishbane,364 most of the studies
published on NAC for the prevention of CI-AKI are quite
small in size, and meta-analyses have been performed to
increase the probability of explaining the full spectrum of
utility for NAC. To date, seven out of the 11 meta-analyses
that have been published on this subject found a net benefit
for NAC in the prevention of CI-AKI.364 However, as pointed
out before, marked heterogeneity in the studies, and
publication bias must lead to the conclusion that ‘‘pooling
of data to arrive at a summary estimate for treatment efficacy
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should generally be avoided in situations where the trials
exhibit significant statistical and/or clinical hetero-
geneity’’.500,501 A recent prospective RCT502 was performed in
patients with decreased kidney function (CrCl p60ml/min
and/or SCr level of X1.1mg/dl [X97.2mmol/l]), comparing a
high oral dose of NAC with high doses of vitamin C. All
patients underwent a coronary angiography. The primary end-
point was the maximum increase of SCr level, and the
secondary end-point was the incidence of CI-AKI, defined as a
relative increase in baseline SCr level of X25% and/or an
absolute increase of X0.5mg/dl (X44.2mmol/l) within 48
hours after contrast-media administration. The maximum
increase of SCr level was significantly lower in the NAC group
than in the ascorbic acid group (0.03±0.18mg/dl [2.65±
15.9mmol/l] vs. 0.04 ± 0.20mg/dl [3.54±17.7mmol/l]),
respectively (P¼ 0.026). The incidence of CI-AKI tended to
be in favor of NAC rather than ascorbic acid, 1.2% vs. 4.4%,
respectively, although this difference was not significant
(P¼ 0.370). It was concluded that an oral high dose of NAC
seemed to be more beneficial than ascorbic acid in preventing
CI-AKI, particularly in diabetic patients with pre-existing CKD.
Finally, a randomized, single-blind, controlled trial was
recently published to assess NAC effects on CI-AKI and
reperfusion injury in ST-segment elevation myocardial
infarction (MI) patients undergoing primary angioplasty
with moderate contrast-media volumes (between 120–230ml
of an iso-osmolar contrast medium).496 The patients under-
going primary angioplasty were randomized to either high-
dose NAC (two times 1200mg/d for 48 hours; or placebo
plus fluids). CI-AKI occurred in 14% of the NAC group and
in 20% of the placebo group (P¼ 0.28). The myocardial
salvage index was also not different between both treatment
groups. Activated oxygen protein products and oxidized low-
density lipoprotein as markers for oxidative stress were
reduced by as much as 20% in the NAC group, whereas no
change was evident in the placebo group.
Thus, despite high-dose i.v. NAC reducing oxidative stress,
it does not provide an additional clinical benefit, compared
to placebo, with respect to CI-AKI and myocardial reper-
fusion injury in nonselected patients undergoing angioplasty.
A recent meta-analysis of all prospective trials of individuals
randomized to either orally or i.v. administered high doses of
NAC, defined as a daily dose greater than 1200mg or a single
periprocedural dose (within 4 hours of contrast-media
exposure) 4600mg, was published by Trivedi et al.497 The
overall effect size, assuming a common OR, was 0.46 (95% CI
0.33–0.63) for the occurrence of CI-AKI with the use of high-
dose NAC. The results of the more conservative random-
effects approach were similar (OR 0.52; 95% CI 0.34–0.78).
Another recently published meta-analysis of RCTs inclu-
ded published trials and conference abstracts (Figure 16).503
The primary and secondary outcomes of interest were
CI-AKI, and renal failure requiring dialysis, respectively.
Ten RCTs met the inclusion criteria. Nine studies compared
combination treatment (bicarbonate and NAC) to NAC and
normal saline; one study compared combination therapy to
NAC alone; one study compared combination therapy to
NAC with normal saline, and a separate arm with NAC and
ascorbic acid. Collectively, combination treatment of NAC
with i.v. sodium bicarbonate reduced CI-AKI by 35%
compared to the other above-mentioned combinations (RR
0.65; 95% CI 0.40–1.05). However, the combination of NAC
plus sodium bicarbonate did not significantly reduce renal
failure requiring dialysis (RR 0.47; 95% CI 0.16–1.41). It was
concluded that combination prophylaxis with NAC and
sodium bicarbonate substantially reduced the occurrence
of CI-AKI overall, but not dialysis-dependent renal failure.
This paper suggests that combination prophylaxis should
be incorporated for all high-risk patients (emergent cases
or patients with pre-existing CKD). Most of the studies
administered NAC orally; some studies used the i.v. route or
even a combination of oral and i.v. There was also a substantial
variation in doses and timing of NAC administration.
One additional study was recently published and was thus
not included in the meta-analysis discussed above. Koc
et al.,504 investigated the efficacy of prophylactic i.v. NAC and
fluids for the prevention of CI-AKI in patients with mild to
moderate renal dysfunction (SCrX1.1mg/dl [X97.2 mmol/l]
or a CrCl p60ml/min) who were undergoing coronary
angiography. A group of patients was assigned to i.v. NAC
(bolus of 600mg twice daily before and on the day of the
procedure) plus high-dose normal saline, a second group to
only high-dose saline, and a third (control) group received
standard saline. Patients in the NAC plus high-dose saline
group received an i.v. bolus of 600mg of NAC twice daily
before and on the day of the coronary procedure (total 2.4 g)
plus i.v. 0.9% saline 1ml/kg/h before, on, and after the day of
the coronary procedure. Patients in the high-dose arm
received the same amount of isotonic saline, while patients
in the control group received an i.v. dose of 0.9% saline
1ml/kg/h for 12 hours before and 12 hours after the coronary
procedure. The rate of CI-AKI in the NAC plus high-dose
saline group was lower than in the high-dose saline group
without NAC. No significant differences in the primary and
secondary end-points were found between the high-dose
saline and control groups.
In conclusion, based on the evidence tables and even
taking the last recent study into account, the overall benefit of
NAC is not consistent or overwhelming. On the other hand,
oral NAC has a low risk of adverse events and usually a low
cost.
THEOPHYLLINE AND FENOLDOPAM IN PREVENTION OF CI-AKI
Theophylline
4.4.4: We suggest not using theophylline to prevent
CI-AKI. (2C)
RATIONALE
A rationale for the prophylactic use of adenosine antago-
nists in patients undergoing radiocontrast procedures was
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suggested by results showing increased serum levels and
urinary excretion of adenosine occurring after intravascular
administration of contrast media.505 The efficacy of theo-
phylline in preventing CI-AKI has been addressed by a
systematic review and meta-analysis in 2005 (nine RCTs, 585
patients),506 and another meta-analysis in 2008 (six RCTs,
629 patients).432 Both meta-analyses indicated a nonsigni-
ficant trend toward a renoprotective effect of theophylline
prophylaxis. The incidence of CI-AKI tended to be
lower (Bagshaw: OR 0.4, CI 0.14–1.16, P¼ 0.09; Kelly: OR
0.49, CI 0.23–1.06, P¼ 0.14), SCr concentrations 48 hours
after intervention were significantly lower (0.17mg/dl;
95% CI 0.2 to 0.06mg/dl [15.0 mmol/l, CI 17.7 to
5.30 mmol/l]; P¼ 0.002) with theophylline compared to
control therapies. However, the overall benefit was small and
findings were inconsistent across studies. The benefit
attributable to the use of theophylline tended to be less
marked in patients receiving iso-osmolar, nonionic contrast
media, and in patients undergoing a predefined saline
protocol.
Neither meta-analysis included a RCT published in 2006
in 150 contrast-media examinations in 91 patients, in which
the renoprotective effects of theophylline, NAC, and the
combination of both were directly compared.507 All patients
had at least one risk factor for developing CI-AKI, and
received more than 100ml of low-osmolar radiocontrast
agent. The incidence of CI-AKI was significantly lower with
theophylline as compared to NAC pretreatment (2% vs. 12%;
P¼ 0.045), and did not differ between theophylline mono-
therapy and the combination treatment. The renoprotective
superiority of theophylline, which was given as a single i.v.
200mg dose 30minutes prior to the procedure, was even
more significant in patients with pre-existing renal damage as
indicated by an SCr 41.5mg/dl (4133 mmol/l) (P¼ 0.008).
Moreover, a recent study508 randomized 217 patients with
eGFR between 30 and 60ml/min who were undergoing
coronary angiography to one of three prophylactic treat-
ments: i.v. isotonic saline (1ml/kg/h for 12 hours before and
after contrast media (group 1, n¼ 72); isotonic saline as in
group 1 together with NAC (600mg p.o. twice daily the
Figure 16 |NAC and bicarbonate vs. NAC for risk of CI-AKI. Reprinted from Brown, JR, Block CA, Malenka DJ et al. Sodium bicarbonate
plus N-acetylcysteine prophylaxis: a meta-analysis. JACC Cardiovasc Interv 2009; 2: 1116–1124,503 copyright 2009, with permission from
American College of Cardiology Foundation; accessed http://interventions.onlinejacc.org/cgi/content/full/2/11/1116
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preceding day and the day of angiography (group 2, n¼ 73);
or isotonic saline and NAC as in group 2 together with
200mg theophylline orally twice daily for the preceding day
and the day of angiography (group 3, n¼ 72). The incidence
of CI-AKI (0.5mg/dl or 44.2 mmol/l SCr increase within 48
hours of intravascular contrast-media injection) was 6.9% in
group 1, 9.6% in group 2, and 0% in group 3 (Po0.03),
suggesting a beneficial effect of adding theophylline to a
standard regimen in the prevention of CI-AKI. Notably, at
least in this study, NAC administration had no additive
protective effect compared to isotonic saline alone.
A very recent study509 randomly assigned patients to
prophylactic administration of saline with sodium bicarbo-
nate plus theophylline (either orally or i.v.) or sodium
bicarbonate only. Theophylline plus bicarbonate prophylaxis
significantly reduced the incidence of CI-AKI (1.6% vs. 7.9%;
P¼ 0.015) compared to bicarbonate alone. Theophylline was
administered either orally (200mg b.i.d. starting the day
before the contrast administration and continuing for 24
hours thereafter) or i.v. 200mg in a short infusion before
contrast administration and continuing orally at 200mg
b.i.d. for 48 hours. Theophylline prophylaxis significantly
reduced the incidence of CI-AKI in moderate and high-risk
patients (0% vs. 8.8%; P¼ 0.022 and 9.1% vs. 42.1%;
P¼ 0.014, respectively). This study did not mention side-
effects of theophylline.
Although these data suggest that preinterventional theo-
phylline administration might be helpful in patients at
increased risk for CI-AKI, the possibility of cardiovascular
side-effects and the interactions with numerous drugs
associated with theophylline510,511 should be recognized
(Suppl Tables 26 and 27). As can be noted from the evidence
profile tables, the evidence is low and the balance of benefits
vs. harm is uncertain. In view of the low evidence and the
uncertain balance of benefits vs. harm, the Work Group
does not support the use of theophylline for prevention of
CI-AKI.
Fenoldopam
4.4.5: We recommend not using fenoldopam to prevent
CI-AKI. (1B)
RATIONALE
Fenoldopam is a selective dopamine A1 receptor agonist
that might theoretically increase blood flow, especially to the
renal medulla. Several uncontrolled studies (historical
controls, retrospective review) suggested that it is effective
in reducing the risk for contrast-induced nephropathy, and
the results of a pilot trial were promising (for review, see
Stacul et al.512). However, two prospective randomized trials
showed negative results.220,513 In the first trial,513 patients
were randomized to saline alone or with fenoldopam
(0.1 mg/kg per minute for 4 hours before and after the
procedure); a third arm was treated with NAC. The incidence
of CI-AKI was similar in the fenoldopam (15.7%) and
control (15.3%) groups, and there was no benefit over
saline alone. A second, larger trial220 also confirmed the
lack of benefit with fenoldopam. In this double-blind trial
of 315 patients, all with saline 0.45%, were randomized to
fenoldopam (0.05 mg/kg per minute titrated to 0.1 mg/kg
per minute) or placebo starting 1 h before the procedure and
continuing for 12 hours afterward. There was no significant
difference in the incidence of CI-AKI within 96 hours in
the two groups (fenoldopam, 33.6%; placebo, 30.1%) or in
the rates of dialysis, rehospitalization, or death at 30 days.
Statins in the prevention of CI-AKI
Two recent studies examined the use of statins in the
prevention of CI-AKI patients with CKD. In the first study,514
31 patients were prospectively randomized to receive atorvas-
tatin 80mg/d or placebo for 48 hours before and 48 hours
after contrast-medium administration. All patients received i.v.
saline and oral NAC. CI-AKI occurred in 16 patients (11%) in
the placebo group and 15 patients (10%) in the atorvastatin
group. Persistent kidney injury, defined as 1-month increase
from baseline creatinine value 425%, was observed in 30%
in the placebo group and in 31% in the atorvastatin group.
The second study515 followed 431 patients, 194 of whom were
receiving pravastatin treatment for hypercholesterolemia. SCr
levels were measured at baseline (preprocedure) and within 48
hours after contrast-medium exposure (peak postprocedure).
Logistic regression analysis revealed that pravastatin treatment,
preprocedure SCr, and contrast volume were independently
related to the decreased risk of CI-AKI. However, such studies
are susceptible to the so-called ‘‘healthy user effect’’ where
certain groups may have reduced risk, not because of the
drug but because of healthier lifestyles, for which use of the
medication is a marker. For example, patients taking statins
may also be more compliant with other medical-care regimens
that may reduce adverse events.
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Chapter 4.5: Effects of hemodialysis or hemofiltration
4.5.1: We suggest not using prophylactic intermittent
hemodialysis (IHD) or hemofiltration (HF) for
contrast-media removal in patients at increased
risk for CI-AKI. (2C)
RATIONALE
Contrast media are excreted mainly by glomerular filtration
and there is a significant correlation between both total body
and renal clearances of contrast media and GFR; the renal
excretion of contrast media will thus be delayed in patients
with renal failure (for review, see Deray).516 Contrast media
can be efficiently removed from blood by IHD and a single
session effectively removes 60–90% of contrast media.516,517
On the basis of these observations, several studies have
explored the prophylactic value of IHD in patients at high
risk, but most of these studies have not demonstrated a
reduced incidence of CI-AKI.516,518 For example, Vogt
et al.518 recorded renal function and other parameters, IHD
requirements, and relevant clinical events before and during 6
days after administration of contrast media in 113 patients
with a baseline SCr 42.3mg/dl (4203 mmol/l). Eight out of
55 patients in the prophylactic IHD group and three in the
non-IHD group (P¼ 0.12), required IHD after contrast-
media examination. Reinecke et al.519 performed a prospec-
tive single-center trial in 424 consecutive patients with
SCr concentrations between 1.3–3.5mg/dl (115–309 mmol/l)
who underwent elective coronary angiography. Patients were
randomized to one of three treatment strategies with all
patients receiving pre- and postprocedural fluids: one group
received no additional therapy, patients in the second group
were hemodialyzed once, and the third group received oral
NAC. The frequency of CI-AKI (defined as an increase in SCr
X0.5mg/dl or X44.2 mmol/l) from 48 to 72 hours after
catheterization was 6.1% in the fluids-only group, 15.9% with
IHD treatment, and 5.3% in the NAC group (intention-
to-treat analysis; P¼ 0.008). There were no differences
between the treatment groups with regard to increased SCr
X0.5mg/dl (X44.2mmol/l) after 30–60 days (4.8%, 5.1%, and
3.1%, respectively; P¼ 0.700). Analyses of long-term follow-
up (range 63–1316 days) by Cox regressions models of the
study groups found quite similar survival rates (P¼ 0.500).
This large study concluded that IHD, in addition to fluids, for
the prevention of CI-AKI provided no evidence for any
outcome benefit but showed evidence for probable harm.
A retrospective but important cohort study of 391 patients
(age 69 ± 8 years, with chronic renal insufficiency [SCr
X1.3mg/dl; X115 mmol/l]) who underwent cardiac cathe-
terization, also did not find any beneficial preventive effect.520
By contrast, Lee et al.521 presented a prospective RCT
indicating that prophylactic IHD might be useful in patients
scheduled for coronary angiography or coronary intervention
with severely impaired renal function (baseline CrCl of 13ml/
min per 1.73 m2). Patients were treated with normal saline at
1ml/kg/h for 6 hours before and 12 hours after contrast-
media administration and randomized to receive IHD for
4 hours as soon as possible after angiography or control
treatment. Four days after angiography, SCr concentrations
were lower in the IHD group compared to the control group.
Out of 42 patients, one patient (2%) in the IHD group but 14
(35%) out of 40 patients in the control group required
temporary IHD after coronary angiography. Furthermore,
none of the 42 patients in the IHD group, but five (13%) out
of 40 patients in the control group, required maintenance
IHD after discharge from the hospital (Po0.05).
A recent meta-analysis of studies using periprocedural
extracorporeal blood purification techniques517 concluded
that such treatments did not decrease the incidence of
CI-AKI. It could theoretically be anticipated that high-flux
membranes used in HF or hemodiafiltration (HDF) moda-
lities should be able to remove contrast media more
efficiently than low-flux membranes used in routine IHD.
However, recent publications on this topic have added to the
controversy about the role of IHD or HF to prevent CI-AKI
(Suppl Tables 28 and 29). Marenzi et al.522 studied 114
consecutive patients with CRF (SCr concentration42mg/dl
or 4177 mmol/l) who were undergoing coronary interven-
tions. Fifty-eight patients were assigned to either HF starting
before the contrast-medium administration and continuing
for up to 24 hours after, while 56 patients were treated with
isotonic saline at a rate of 1ml per kilogram of body weight
per hour, given in a step-down unit over the same time
interval. In-hospital mortality was 2% in the HF group and
14% in the control group (P¼ 0.02), and the cumulative
1-year mortality was 10% and 30%, respectively (P¼ 0.01).
Temporary RRT was required in 25% of the control group
and in only 3% of the patients in the HF group. An increase
in the SCr concentration of 425% from the baseline value
after the coronary intervention occurred less frequently
among patients in the HF group than among the control
patients (5% vs. 50%, Po0.001). The effective removal of
creatinine during HF or IHD makes it difficult to be certain
that an observed lower incidence of CI-AKI is not related to
the transport removal of creatinine during the procedure.
In a subsequent study, the same authors523 randomized
92 patients with CKD (CrCl p30ml/min) to three different
prophylactic treatments: i.v. isotonic saline (control group);
i.v. saline for 12 hours before contrast-media exposure,
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followed by HF for 18–24 hours after contrast-media
exposure; and a third group where HF was performed for 6
hours before and for 18–24 hours after contrast-media
exposure. The incidence of CI-AKI (425% increase in
SCr) and the in-hospital clinical course were compared in the
three groups. In-hospital mortality was 20%, 10%, and 0%,
respectively, in the three groups; IHD was required in nine
(30%), 3 (10%), and zero (0%) patients, respectively
(P¼ 0.002). According to these results, pre-HF is required
to obtain the full clinical benefit, suggesting that among
different mechanisms possibly involved, high-volume con-
trolled volume expansion before contrast-media exposure
plays a major role in prevention. This study further suggests
that bicarbonate exposure with HF may ultimately have been
the mechanism for the lower CI-AKI incidence (Suppl Table
29). In summary, the evidence profile for IHD vs. HF showed
low-quality evidence and an uncertain benefit vs. harm
balance of HF/IHD in preventing CI-AKI in patients with
severe CKD. Given the costs and logistical difficulties, the use
of HF modalities for CI-AKI prevention can only be
advocated if future studies will convincingly show clear
benefit.
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